Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Inclusion Criteria: * Patients ≥ 18 years of age * ALK+ ALCL * Histologically confirmed relapse after having achieved a PR or CR with conventional therapy * Refractoriness to conventional chemotherapy (SD or PD after conventional chemotherapy) * Not able to receive conventional chemotherapy (e.g. due to comorbidities) * Adequate organ function, defined as the following: * Absolute neutrophil count ≥ 1,500/μL unless there is known hematologic/solid tumor marrow involvement * Platelet count ≥ 75,000/ μL unless there is known marrow involvement of the disease * Total bilirubin must be \< 1.5 x the upper limit of the normal (ULN) unless the elevation is known to be due to Gilbert syndrome. * ALT or AST must be \< 3 x the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of hematologic/solid tumor in liver. * Serum creatinine must be \< 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance \> 40 mL/minute. * Hemoglobin must be ≥ 8g/dL. * Written, voluntarily signed informed consent * Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, must practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent until 6 months after the last doses of BV and until last doses of imatinib, whatever occurs later, or agrees to complet…